Tag: Epidiolex

Avatar photoDebra BorchardtSeptember 27, 2018
epidiolex-medical-marijuana-1280x800-1280x800.jpg
Business

DEA Classifies GW Pharmaceutical’s Epidiolex As A Schedule 5 Drug

5min00
The Acting Administrator of the Drug Enforcement Administration has placed FDA-approved drugs that contain CBD derived from cannabis and no more than 0.1 percent tetrahydrocannabinols  (THC) in schedule V. GW Pharmaceutical’s (GWPH) Epidiolex had been a schedule I controlled substance, with this new directive Epidiolex (and any generic versions of the same formulation that might be […]
CONTINUE READING
Avatar photoDebra BorchardtJune 25, 2018
epidiolex-medical-marijuana-1280x800-1280x800.jpg
Business

FDA Approves GW Pharmaceutical’s Cannabis Drug Epidiolex, Rescheduling Expected In 90 Days

8min01
The U.S. Food and Drug Administration (FDA) approved GW Pharmaceuticals’ (GWPH) cannabidiol (CBD) drug Epidiolex as an oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome, and Dravet syndrome, in patients two years of age and older. According to the press release, this is the first FDA-approved […]
CONTINUE READING

Newer Posts

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.

 Sign up

About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis

READ MORE
Company